Home  |  Contact

Cellosaurus NK-92 (CVCL_2142)

[Text version]

Cell line name NK-92
Synonyms NK92; Natural Killer-92; NK-92.05; Neukoplast; aNK
Accession CVCL_2142
Resource Identification Initiative To cite this cell line use: NK-92 (RRID:CVCL_2142)
Comments Part of: LL-100 blood cancer cell line panel.
Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections.
Characteristics: IL2 dependent.
Characteristics: Does not express FCGR3A/CD16.
Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: Transcriptome analysis.
Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.
Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
Derived from sampling site: Peripheral blood.
Disease Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_W733 (GFP-CD16-F/F.NK-92)CVCL_W734 (GFP-CD16-V/V.NK-92)CVCL_IM23 (haNK)
CVCL_VN54 (laNK)CVCL_VN56 (NK-92 GFP)CVCL_VN57 (NK-92.26.5)
CVCL_U271 (NK-92CI)CVCL_3755 (NK-92MI)CVCL_V429 (NoGFP-CD16.NK92)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): ATCC; DSMZ

vWA16,18 (DSMZ)
18 (ATCC)

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/NK-92

Gong J.-H., Maki G., Klingemann H.-G.
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
Leukemia 8:652-658(1994)

Klingemann H.-G., Wong E., Maki G.
A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Biol. Blood Marrow Transplant. 2:68-75(1996)

PubMed=10365666; DOI=10.1089/10430349950018030
Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G.
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Hum. Gene Ther. 10:1359-1373(1999)

PubMed=10803505; DOI=10.1038/sj.leu.2401778
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.
Leukemia 14:777-782(2000)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11454312; DOI=10.1089/152581601750288975
Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K.
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.
J. Hematother. Stem Cell Res. 10:369-383(2001)

PubMed=12850795; DOI=10.1080/14653240310001523
Tam Y.K., Martinson J.A., Doligosa K., Klingemann H.-G.
Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Cytotherapy 5:259-272(2003)

PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392
Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M.
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
J. Immunol. 180:6392-6401(2008)

PubMed=19194464; DOI=10.1038/leu.2009.3
Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H., Klinkebiel D., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K., Tsui I.F.L., Ali H., Shimizu N., Au W.Y., Lam W.L., Chan W.C.
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
Leukemia 23:1139-1151(2009)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767-904767(2010)

PubMed=21052088; DOI=10.1038/leu.2010.255
Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.Y., Srivastava G., Greiner T.C., Kucuk C., Deffenbacher K., Vose J., Smith L., Au W.Y., Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H., Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.C.
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
Leukemia 25:348-358(2011)

PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010
Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M.
Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.
Mol. Immunol. 48:1512-1517(2011)

PubMed=25586472; DOI=10.1038/ncomms7025
Kucuk C., Jiang B., Hu X., Zhang W., Chan J.K.C., Xiao W., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W., Cornish A., Gong Q., Yang Q., Sun H., d'Amore F., Leppa S., Liu W., Fu K., de Leval L., McKeithan T., Chan W.C.
Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.
Nat. Commun. 6:6025-6025(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x
Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S., Klingemann H.-G., Tonn T.
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2
Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C., Eom K.-S., Kim S.W.
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
J. Immunother. Cancer 7:138.1-138.17(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

Cell line collections AddexBio; C0003026/NA - Discontinued
ATCC; CRL-2407
ATCC; PTA-6670 - Discontinued
BCRC; 60414 - Discontinued
Cell line databases/resources CCRID; 3131C0001000200020
CCRID; 3142C0001000000949
Cell_Model_Passport; SIDM01143
Lonza; 1093
Ontologies BTO; BTO:0003287
CLO; CLO_0008177
Biological sample resources BioSample; SAMN03471836
Gene expression databases ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM472001
Other Wikidata; Q17149636
Polymorphism and mutation databases Cosmic; 1534874
Cosmic; 1542071
Cosmic; 2025326
Cosmic; 2390215
Cosmic; 2785204
Entry history
Entry creation04-Apr-2012
Last entry update20-May-2021
Version number24